Entos Pharmaceuticals’ Post

View organization page for Entos Pharmaceuticals, graphic

5,706 followers

The Entos team is pleased to announce that we have received approval from Health Canada | Santé Canada to to initiate a phase 1/2 clinical trial for our COVID-19 vaccine booster, Covigenix VAX-002. COVID-19 is still a serious public health issue, especially in developing countries. Covigenix VAX-002 has the potential to be the first DNA fridge-stable vaccine offering longer-lasting protection than any other vaccine on the market. Today’s announcement is also particularly special as this will be our first GMP clinical vaccine manufactured completely in-house by Entos at our new manufacturing facility in Carlsbad, CA. Learn more here: https://lnkd.in/gPBTRrpB

Entos Pharmaceuticals Receives Approval from Health Canada to Begin Clinical Trial for COVID-19 Vaccine Booster

Entos Pharmaceuticals Receives Approval from Health Canada to Begin Clinical Trial for COVID-19 Vaccine Booster

businesswire.com

Amit Singh

Team, Project and Program Leader | Nanoparticle Formulations | Process Development/CMC | Analytics/Bioanalytics | Targeted Delivery | Strategy | Gene & Cell Therapy |

4mo

Congrats Arun Raturi and the team for this feat!! Kudos and good luck going forward!!

Jag Sindhu, MBA

Senior Director of Business Development at M3 Wake Research

4mo

Congratulations Entos Pharmaceuticals 👏

Armaan Siddiqui

PhD Student at IIT Bombay Cell and Tissue Engineering Lab l Non viral gene delivery

4mo

Congratulations Entos Team.

Marty Henehan

Vice President of Business Development – Head of North America

4mo

Amazing news. Congratulations

Amy Walker

PhD | Chief Operating Officer

4mo

Hugely impressive! Congrats Entos team

Launa Aspeslet

Multi-time C-Suite Executive | Experienced Board Member

4mo

Congrats!!

Eric Fuog

Scientific Director, Pharmaceutical Sciences at Takeda

4mo

Congratulations!

Dr. Tulika Anthwal

PhD (Pharmaceuticals chemistry)

4mo

Congratulations!

See more comments

To view or add a comment, sign in

Explore topics